Metabolic testing in the pediatric epilepsy unit

Area of Science:

• Pediatric Neurology
• Metabolic Disorders
• Epilepsy

Background:

• Unexplained developmental delay affects up to 3% of the population.
• Epilepsy is present in over 30% of individuals with unexplained developmental delay.
• Current metabolic testing approaches lack standardization for this patient group.

Purpose of the Study:

• To retrospectively evaluate the extent and findings of metabolic testing in children with developmental delay and epilepsy.
• To identify the prevalence of metabolic abnormalities, including mitochondrial dysfunction and carnitine deficiency.
• To advocate for a standardized metabolic testing approach.

Main Methods:

• Retrospective review of 429 children admitted to a pediatric epilepsy-monitoring center in 2005.
• Analysis of patient records for developmental delay, epilepsy type, and metabolic testing performed.
• Correlation of metabolic testing results with clinical findings like multifocal interictal discharges and medication use (valproic acid).

Main Results:

• Ninety percent of patients had developmental delay; 20% underwent metabolic testing.
• Abnormal results suggesting mitochondrial dysfunction were found in 28% of patients without a prior diagnosis.
• Metabolic abnormalities were identified in 75% of patients with multifocal interictal discharges.
• Secondary carnitine deficiency was diagnosed in 22% of patients on valproic acid.

Conclusions:

• Primary or secondary metabolic abnormalities are significant findings in children with developmental delay and epilepsy.
• Mitochondrial dysfunction should be strongly considered in the differential diagnosis.
• Carnitine deficiency is identifiable and treatable, highlighting the need for systematic metabolic evaluation.